T1452

TPCA-1

≥95% (HPLC), IκB kinase-2 (IKK-2) Inhibitor, powder

• Synonyme(s) : [5-(p-Fluorophenyl)-2-ureido]thiophene-3-carboxamide
• Formule empirique (notation de Hill) : C₁₂H₁₀FN₃O₂S
• Numéro CAS: 507475-17-4
• Poids moléculaire : 279.29
• UNSPSC Code: 12352200
• PubChem Substance ID: 329826675
• NACRES: NA.77
• MDL number: MFCD09037541
• Assay: ≥95% (HPLC)
• Form: powder

Propriétés

• Nom du produit: TPCA-1, ≥95% (HPLC)
• Quality Segment: 100
• assay: ≥95% (HPLC)
• form: powder
• color: white to light brown
• solubility: DMSO: 5 mg/mL, clear
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: NC(=O)Nc1sc(cc1C(N)=O)-c2ccc(F)cc2
• InChI: 1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18)
• InChI key: SAYGKHKXGCPTLX-UHFFFAOYSA-N

Description

Application

TPCA-1 has been used to study its cytotoxic effects in RPMI8226 and LP1 cell lines. It has also been used as a culture media supplement for nuclear protein fractions extracted from human airway smooth muscle cells.

Biochem/physiol Actions

IKK-2 Inhibitor

TPCA-1 is a potent and selective inhibitor of human IκB kinase-2 (IKK-2) with IC₅₀ = 17.9 nM for IKK-2 compared to 400nm for IKK-1. It has been used to study inhibition of IKK-2 to prevent inflammatory mediator release in animal models of arthritis and airway inflammation.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

TPCA-1 is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. It is insoluble in water.

Informations sur la sécurité

• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• ppe: dust mask type N95 (US), Eyeshields, Gloves